Last reviewed · How we verify
Dipeptiven
At a glance
| Generic name | Dipeptiven |
|---|---|
| Also known as | Dipeptamin |
| Sponsor | Menoufia University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Citrullinemia for the Prediction of Enteral Nutrition Tolerance Among Critically Ill Patients (NA)
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) (PHASE2)
- Perioperative Supplementation With Immunonutrition and Its Impact on Surgical Outcome and Pain in Oral Cavity or Mandibular Tumours (NA)
- Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy (NA)
- Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF (PHASE3)
- Effect of Parenteral Glutamine on Myocardial Injury and Inflammation Biomarkers (NA)
- Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients (NA)
- Preoperative Immunonutrition and Cardiac Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dipeptiven CI brief — competitive landscape report
- Dipeptiven updates RSS · CI watch RSS
- Menoufia University portfolio CI